RAPT Therapeutics Inc
RAPT7.840USD
+6.810+661.17%
Close 06/17, 16:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
More Details of RAPT Therapeutics Inc Company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
Company Info
Ticker SymbolRAPT
Company nameRAPT Therapeutics Inc
IPO dateOct 31, 2019
Founded at2015
CEODr. Brian Wong, M.D., Ph.D.
Number of employees68
Security typeOrdinary Share
Fiscal year-endOct 31
Address561 Eccles Ave
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94080
Phone16504899000
Websitehttps://rapt.com/
Ticker SymbolRAPT
IPO dateOct 31, 2019
Founded at2015
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Rodney K. B. Young
Mr. Rodney K. B. Young
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Linda Kozick
Ms. Linda Kozick
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Michael F. Giordano, M.D.
Dr. Michael F. Giordano, M.D.
Independent Director
Independent Director
--
--
Dr. William (Bill) Ho, M.D., Ph.D.
Dr. William (Bill) Ho, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
--
--
Ms. Lori Lyons-Williams
Ms. Lori Lyons-Williams
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Brian Wong, M.D., Ph.D.
Dr. Brian Wong, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Dirk Brockstedt, Ph.D.
Dr. Dirk Brockstedt, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Shareholders
Shareholders
Proportion
Medicxi Ventures (UK) LLP
16.90%
OrbiMed Advisors, LLC
9.93%
TCG Crossover Management, LLC
9.90%
Foresite Capital Management, LLC
9.45%
RTW Investments L.P.
8.89%
Other
44.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
2.96%
Private Equity
2.84%
Hedge Fund
2.64%
Venture Capital
2.25%
Investment Advisor
1.68%
Research Firm
0.08%
Individual Investor
0.06%
Bank and Trust
0.01%
Family Office
0.01%
Other
87.49%
Institutional Shareholding
Updated: Tue, Mar 4
Updated: Tue, Mar 4
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
301
145.36M
110.11%
+83.62M
2024Q4
309
140.52M
106.54%
+100.36M
2024Q3
304
31.22M
87.82%
-13.95M
2024Q2
305
33.18M
93.85%
-9.52M
2024Q1
295
33.76M
95.60%
-5.47M
2023Q4
282
36.46M
106.02%
-3.53M
2023Q3
281
36.40M
105.98%
-3.26M
2023Q2
295
35.63M
103.77%
-4.21M
2023Q1
301
34.71M
101.29%
-3.14M
2022Q4
290
33.55M
97.48%
-1.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Medicxi Ventures (UK) LLP
22.35M
16.93%
+22.35M
--
Dec 31, 2024
OrbiMed Advisors, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
TCG Crossover Management, LLC
13.14M
9.95%
+13.14M
--
Dec 31, 2024
Foresite Capital Management, LLC
12.50M
9.47%
+12.50M
--
Dec 31, 2024
RTW Investments L.P.
11.76M
8.91%
+11.76M
--
Dec 31, 2024
BVF Partners L.P.
9.24M
7%
+9.24M
--
Dec 31, 2024
The Vanguard Group, Inc.
2.93M
2.22%
-8.95K
-0.30%
Jan 31, 2025
Redmile Group, LLC
6.48M
4.91%
+5.97M
+1.18K%
Dec 31, 2024
Deep Track Capital LP
6.01M
4.55%
+6.01M
--
Dec 31, 2024
Adar1 Capital Management LLC
1.17M
0.89%
+1.17M
+15.56K%
Dec 31, 2024
View more
Related ETFs
Updated: Fri, Jun 6
Updated: Fri, Jun 6
Name
Proportion
Federated Hermes MDT Small Cap Core ETF
0.05%
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
Nuveen ESG Small-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
Humankind US Stock ETF
0%
Invesco Dorsey Wright Healthcare Momentum ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Proshares Ultra Russell 2000
0%
View more
Federated Hermes MDT Small Cap Core ETF
Proportion0.05%
iShares Micro-Cap ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
Nuveen ESG Small-Cap ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Humankind US Stock ETF
Proportion0%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
